The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study.
 
Li Zheng
No Relationships to Disclose
 
Dai Ruihong
No Relationships to Disclose
 
Ying Jieer
No Relationships to Disclose
 
Qi Xu
No Relationships to Disclose
 
Zengqing Guo
No Relationships to Disclose
 
Changlu Hu
No Relationships to Disclose
 
Yuping Sun
Honoraria - AstraZeneca; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Pfizer; Roche
 
Zuoxing Niu
No Relationships to Disclose
 
Jihui Hao
No Relationships to Disclose
 
Mingjun Zhang
No Relationships to Disclose
 
Dai Guanghai
No Relationships to Disclose
 
Dong Hua
No Relationships to Disclose
 
Yueyin Pan
No Relationships to Disclose
 
Xin Wang
No Relationships to Disclose
 
Shuqing Wei
No Relationships to Disclose
 
Xiaobing Chen
No Relationships to Disclose
 
Xinhe Yu
Employment - Innovent Biologics (Suzhou) Co., Ltd
 
Yulong Zhang
Employment - Innovent Biologics (Suzhou) Co., Ltd
 
Hui Zhou
Employment - Innovent Biologics
 
Feng Bi
No Relationships to Disclose